The Keystone State Ride (KSR) will be September 8-14, 2024 to raise funds for Penn Medicine’s Abramson Cancer Center. This six day van supported road bike tour averages 72 miles a day, and begins in Pittsburgh and finishes in Philadelphia after completing 400+ miles. Includes transportation from Philly to Pittsburgh, hotels, luggage transfers, and SAG van support. See sponsors below for a listing of hotels. The KSR culminates with the Breakthrough Challenge ride at the Daniel Boone Homestead on September 15, 2024 where we celebrate the success of both fundraisers for cancer research.
The Keystone State Ride funds bold and innovative cancer research at Penn Medicine’s Abramson Cancer Center. The Keystone State Ride donates 100% of participant-raised funds directly to innovative cancer research at Penn Medicine’s Abramson Cancer Center, providing critical funding to achieve major breakthroughs in cancer therapeutics and care that will ultimately benefit cancer patients globally. The Keystone State Ride stages an annual event to fulfill this vital mission and further build community among its participants. The Keystone State Ride strives to encourage diversity and maintain an environment free from discrimination, where participants treat each other with respect, dignity, and courtesy.
The Keystone State Ride is affiliated with the Breakthrough Bike Challenge which is a 501(c)(3) nonprofit organization registered in the United States of America under EIN 46-5471970 to benefit research at Penn Medicine’s Abramson Cancer Center. Let us help you set-up a fundraising page to start collecting tax deductible donations that are deposited directly to this organization. Learn more about the impact of the more than $2.25M raised by these events at www.ms-stride.org/breakthroughchallenge/
Copyright © 2024 Keystone State Ride - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.